PPP: Stable margins and dividend income but illiquid stock limits conviction
Intrinsic value VND 20,626 vs market VND 18,400; implied upside 12.1% (confidence: low).
Business Overview
Công ty Cổ phần Dược phẩm Phong Phú (PPP) is an HNX-listed pharmaceutical company operating in the domestic generic and OTC segment (ICB: Dược phẩm). The company has issued 8,799,991 shares and reports stable profitability: gross margin 35.3% and EBIT margin 15.2% alongside net profit margin 13.3% (latest reported ratios).
Investment Thesis
PPP combines margin durability and a shareholder-friendly cash return profile (dividend yield 8.2%) with modest growth: 3-year revenue moved from VND 152.2 bn in 2023 to VND 139.7 bn in 2025 and net profit roughly VND 20.1 bn (2023) -> VND 18.6 bn (2025). The stock trades at P/E 8.7 and P/B 1.2, implying value relative to earnings and book. Our blended intrinsic value (DCF 70% / PE 30%) yields VND 20,626 per share; key model inputs include base FCF and a WACC of 10% with terminal growth 4%.
Valuation Commentary
Blend of a DCF (70%) and a relative PE approach (30%) to derive a per-share intrinsic value.
- Base free cash flow in the model: VND 24,713,352,145 (reported as base_fcf input).
- DCF intrinsic component: VND 49,047.5 per share; PE-derived component: VND 18,106.7 per share; blend weights 0.7/0.3 produce VND 20,626.
- WACC 10.0% and terminal growth 4.0% (model_inputs).
- Net cash position in model: approximately VND 3.3 bn (net_debt negative).
- Sanity flags: stock classed as illiquid and upside capped for liquidity.
The implied upside of 12.1% is positive but limited given model confidence is low and the stock is illiquid. The DCF component is materially higher than the blended result (DCF per-share 49,047.5), indicating sensitivity to WACC/terminal assumptions; small changes in WACC or terminal growth would move the intrinsic value substantially. Given limited trading liquidity and concentrated ownership, execution risk reduces valuation confidence.
Bull vs Bear
- Attractive income profile: dividend yield 8.2% provides income while investors wait for rerating.
- Healthy profitability: gross margin 35.3% and EBIT margin 15.2% support operating cash generation.
- Modest leverage: Debt/Equity 0.27 gives balance-sheet flexibility and model shows net cash (~VND 3.3 bn).
- Low liquidity: avg volume over 2 weeks is only 157 shares and model flagged the stock as illiquid, increasing transaction and exit risk.
- Large shareholder concentration: top holder owns 45.96%, which can limit free float and corporate governance visibility.
- Model confidence is low and DCF/PE components diverge (DCF per-share VND 49,047.5 vs PE per-share VND 18,106.7), signalling valuation sensitivity to assumptions.
Sector Context
The domestic pharmaceutical sector is characterized by fragmented generics, pricing pressure from public procurement and strong importance of distribution networks; VAS accounting differences can affect reported margins and inventories relative to international peers. Our sector median implied upside is 12.0%, so PPP's 12.1% is roughly in line with peers. Regulatory dynamics (price reviews, MOH procurement lists) and product registration timelines matter for growth trajectories. For listed Vietnamese pharma names, foreign ownership room and liquidity constraints are common; PPP has non-trivial foreign room in absolute shares but its two-week average volume is very low, making it less accessible to larger institutional flows.
Risk Factors
- Very low liquidity (avg_volume_2w 157 shares) — market impact and exit risk for larger orders.
- High ownership concentration (largest shareholder 45.96%) — potential for controlling-shareholder actions that may not align with minority holders.
- Model confidence is low — intrinsic value is sensitive to WACC/terminal growth; DCF vs PE divergence raises valuation uncertainty.
- Modest recent revenue trajectory: revenue fell from VND 152.2 bn (2023) to VND 139.7 bn (2025), suggesting limited top-line momentum.
- Regulatory risk: changes to MOH procurement or price caps could compress margins despite current gross margin of 35.3%.
- Small reported net cash (model net_debt ~ -VND 3.3 bn) — balance-sheet comfortable but not a large buffer for shocks.
Catalysts
- Interim or special dividend announcements (company already shows a high dividend yield historically).
- Better-than-expected tender wins or new product registrations that accelerate top-line recovery from VND 139.7 bn (2025).
- Any reduction in share-concentration or steps improving free float/liquidity would likely narrow the liquidity discount.
- Recalibration of market WACC/interest rates or sector re-rating that increases permitted PE multiples from the current fair_pe of 8.59.
Forensic Assessment
There are no M-Score or forensic red flags in the input and no explicit warnings in forensic.red_flags. Earnings quality is moderate-to-good at 77.1/100, which reduces immediate concerns about manipulation. Nonetheless, high ownership concentration (45.96%) and limited disclosure that often accompanies tightly held small-caps warrant ongoing monitoring of related-party transactions and cash flows.
Track Record
Model track record spans 12 years with a hit rate of 72.7% and an average historical upside of 111.8% in years when the model called >10% upside — a respectable record that supports using the model as a reference. That said, past performance is not a guarantee and the current model's confidence is low, so historical success should be tempered by present liquidity and valuation sensitivity issues.
Written by a language model on 2026-08-10 from this page’s own model outputs and financial statements, and may quote figures from that date. Descriptive analysis, not investment advice — no buy, sell or hold recommendation is given or implied.